Companies › Camurus
1 active drug program in 2 registered trials: 1 Phase 3, 1 Phase 2; Gastroenterology; next expected readout Nov 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| CAM2029 Somatostatin receptor agonist (octreotide subcutaneous depot) | SSTR2 | Phase 3 | Gastro-enteropancreatic Neuroendocrine Tumor; Polycystic Liver Disease | Nov 2026 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT05050942 | CAM2029 | Phase 3 | Gastro-enteropancreatic Neuroendocrine Tumor | Gastroenterology | Nov 2026 |
| NCT05281328 | CAM2029 | Phase 2 | Polycystic Liver Disease | Gastroenterology | Aug 2027 |
Advanced Accelerator Applications VectivBio Pharmicell Akero Therapeutics LyGenesis
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.